Researchers at the University of Pennsylvania have gained new insight into how different inflammatory conditions reinforce each other via trained innate immunity.

A handful of developers are advancing drug prospects in the localized scleroderma (LS) space, with candidate mechanisms that range from cell-based gene therapy to IL-4 or IL-6 antagonism to PDE4 blocking, and with efforts that involve approved as well as experimental compounds.

Screening a panel of potential autoantigens, investigators at the Karolinska Institute have identified four autoantigens that are targeted by the T cells of multiple sclerosis patients.

A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men.

Versant Ventures is committing $50 million in series A funding to Cimeio Therapeutics Inc., which aims to bring new possibilities in terms of disease targeting and safety to bear on a wide range of cell therapy applications, including hematopoietic stem cell transplantation (HSCT) and adoptive cell transfer.